Navigation Links
DURECT in Medical News

Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT

CUPERTINO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX ) today reported that Endo Pharmaceuticals (Nasdaq: ENDP ) has given notice that it is returning to us Endo's rights in the U.S. and Canada to develop and commercialize TRANSDUR(TM)-Sufentanil, a propriet...

DURECT Corporation Announces Second Quarter 2009 Financial

...UPERTINO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today fina.../prnh/20020717/DRRXLOGO ) At June 30, 2009, durect had cash and investments of $41.9 million, compare...(TM) (SABER(TM)-Bupivacaine). During the quarter, durect continued enrollment in our approximately 6...

DURECT to Present at the BMO Capital Markets Healthcare Conference

...PERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that...com/cgi-bin/prnh/20020717/DRRXLOGO ) About durect Corporation durect is an emerging specialty pharmaceutical company de...

DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call

... 27 /PRNewswire-FirstCall/ -- In conjunction with durect Corporation's (Nasdaq: DRRX ) second quarter 200...in the "Investor Relations" section. About durect Corporation durect is an emerging specialty pharmaceutical company de...

REMOXY(R) NDA Update

...UPERTINO, Calif., July 7 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) today reported that ... Corporate Relationships In December 2002, durect licensed to Pain Therapeutics, Inc. the right to d...ied opioid compounds. Under the license agreement, durect is reimbursed for formulation and other work perfo...

DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy

...PERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that Dr. Joseph Stauffer has joined durect as Chief Medical Officer and Executive Vice Presid...ucts," stated James E. Brown, President and CEO of durect Corporation. "We're looking forward to the impact...

DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call

...l 28 /PRNewswire-FirstCall/ -- In conjunction with durect Corporation's (Nasdaq: DRRX ) first quarter 2009...n the "Investor Relations" section. About durect Corporation durect is an emerging specialty pharmaceutical company de...

DURECT to Participate in Cowen and Company Healthcare Conference

...PERTINO, Calif., March 9 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that...e in the "Investor Relations" section. About durect Corporation durect is an emerging specialty pharmaceutical company de...

Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results

...nt of oral mucositis, was on clinical hold, while EN 3270 was licensed from durect Corporation and in Phase II development for the treatment of moderate-to-severe chronic pain. Endo will return to durect all development rights to its transdermal sufentanil patch. 2009 Fina...

DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call

...b. 2 /PRNewswire-FirstCall/ -- In conjunction with durect Corporation's (Nasdaq: DRRX ) fourth quarter 200...e in the "Investor Relations" section. About durect Corporation durect is an emerging specialty pharmaceutical company de...
DURECT in Medical Technology

ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia

CUPERTINO, Calif., June 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX ) announced today that the US Food and Drug Administration (FDA) has granted to DURECT orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia (PHN). Bup...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

...ERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today posi...therapy," stated James Brown, President and CEO of durect Corporation. "We believe that our small, patient-...t to partner or to progress ourselves. About durect Corporation ...

REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted

...PERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that ... release dosage forms on the market today. About durect Corporation durect is an emerging specialty pharmaceutical company de...

DURECT Announces Positive ELADUR(TM) Phase IIa Study Results

...PERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today posit...d characteristics of analgesic activity of ELADUR. durect anticipates that detailed results will be submitte...lock, epidural and intrathecal anesthesia. About durect Corporation ...

Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)

...UPERTINO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that ...dded benefit of being less prone to abuse. About durect Corporation durect Corporation is an emerging specialty pharmaceutica...

DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp

...nds among women, but no positive effect among men. durect has not independently verified the analysis perfor...eking a potential partner for the program. About durect Corporation durect Corporation is an emerging specialty pharmaceutica...
DURECT in Biological Technology

DURECT Corporation Announces Third Quarter 2008 Financial Results

...UPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today finan...les based milestones. If ELADUR is commercialized, durect would also receive royalties on product sales. Alp...chive in the "Investor Relations" section. About durect Corporation ...

DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective

...PERTINO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that ...arma Ireland Limited and DURECT, Alpharma has paid durect an upfront license fee of $20 million, with possib...les based milestones. If ELADUR is commercialized, durect would also receive a royalty on product sales. Alp...

New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone)

...PERTINO, Calif., June 10 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that ...er). Corporate Relationships In December 2002, durect licensed to Pain Therapeutics, Inc. the right to d...d drug candidates. In addition, if commercialized, durect will receive royalties for Remoxy and certain othe...

DURECT Corporation to Participate in Upcoming Healthcare Conferences

...UPERTINO, Calif., June 6 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that ...chive in the "Investor Relations" section. About durect Corporation durect Corporation is an emerging specialty pharmaceutica...

DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results

...UPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today finan...r the same period in 2006. At December 31, 2007, durect had cash and investments of $62.0 million, compare... over existing therapeutics." Highlights for durect in Fiscal Year 2007 include: -- Remoxy. In Dece...

DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call

.... 31 /PRNewswire-FirstCall/ -- In conjunction with durect Corporation's (Nasdaq: DRRX ) fourth quarter 2007...chive in the "Investor Relations" section. About durect Corporation durect Corporation is an emerging specialty pharmaceutica...

DURECT to Host Webcast in Conjunction with an Analyst's Day on October 17

...PERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that ...wscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) About durect Corporation durect Corporation is an emerging specialty pharmaceutica...

Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIG's Plenary Panel in Vegas

...feTech Innovations -- Maggie Pax, Senior Director, Business Development, MicroCHIPS -- Michael Arenberg, Executive Director, Business Development, durect -- Fernando Alvarez-Nunez, PhD, Principal Scientist, Small Molecule Pharmaceutics, Amgen -- Ashutosh Sharma, PhD, Executive Vice President, V...

DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference

...PERTINO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- durect Corporation (Nasdaq: DRRX ) announced today that ...rchive in the "Investor Relations" section. About durect Corporation durect Corporation is an emerging specialty pharmaceutica...
Other Tags
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
Other Contents